Latest News
October 1, 2010
Embera NeuroTherapeutics'
Lead Candidate,
EMB-001, Supported by $3.9M Grant from National Institute on Drug Abuse
April 26, 2010
Newly-Created Company, LipimetiX,
Focused on Peptide Therapeutics for High Risk Cardiovascular Patients
February 16, 2010
Embera NeuroTherapeutics
Forms Clinical Development Collaboration
with Exponential Pharma Partners
Collaborative Development for New Therapeutics Collaborative Development for New Therapeutics
Exponential Pharma Partners create new business ventures in collaboration with commercial pharmaceutical companies to efficiently develop novel early-stage therapeutics. We leverage our operating and deal-making experience to match entrepreneurs, technologists, researchers, contract research organizations, and investors. Because we work collaboratively with our pharma partners from venture creation through clinical proof-of-concept, the results are focused and efficient ventures that quickly translate new science into the clinic, effectively responding to both the needs of entrepreneurs and the companies that eventually market the biopharmaceutical products.